Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo to upadacitinib
- Development stage
- Unknown
- Lead developer
- AbbVie
- Administration
- Oral
01
Overview
Placebo to upadacitinib is an inactive control substance developed by AbbVie for use in clinical trials evaluating upadacitinib (Rinvoq), a selective Janus kinase 1 (JAK1) inhibitor. In the context of atopic dermatitis, it is formulated as an oral extended-release tablet to match the appearance and administration schedule of the active drug. It serves as a comparator in Phase 3 studies, such as the 'Heads Up' trial, to establish a baseline for safety and efficacy. As a placebo, it contains no active pharmaceutical ingredients and does not exert a therapeutic effect.
- Other names
- placebo to upadacitinib-AbbVie-atopic dermatitisupadacitinib placebo
Beyond the preview
Go deeper on placebo to upadacitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo to upadacitinib.